The new safety data from Phase III and I trials showing an absence of postinjection syndrome, a rare and serious side effect ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced new positive efficacy, safety and ...

Newron today announces its financial and operational results for the half year ended June 30, 2024, and provides an update on ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

with a statistically significant reduction from baseline in the Positive and Negative Syndrome Scale (PANSS) total score after six weeks compared to placebo. It appears shareholders were spooked ...

Participants were required to respond on an analogue scale indicating the degree to ... questions related to the constructs measured on the PANSS and the CDS items, while being compatible with ...

The long-term safety of TEV-‘749 and incidence of PDSS are also being evaluated in the SOLARIS open-label study (Period 2), with safety data topline readout expected in the first half of 2025.

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

which said ulotaront was unable to show a statistically significant improvement over placebo on the primary endpoint – the change from baseline in Positive and Negative Syndrome Scale (PANSS ...

These smart scales will help you access all the comprehensive data and metrics you need to track your weight journey. I'm a Fitness & Nutrition writer for CNET who enjoys reviewing the latest ...